In 2024, the FDA is thinking of copyright for therapeutic use along with psychological intervention in people with PTSD, given that the company has accepted an software from Lykos Therapeutics."The SAP is simply accessible for sure major clinical disorders, is designed for crisis foundation only, and patients can't possess [the compound] but has to